These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36312539)

  • 1. Impact and challenges of enactment for advanced regenerative medicine in South Korea.
    Kim DS; Bae S
    Front Bioeng Biotechnol; 2022; 10():972865. PubMed ID: 36312539
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Japan's challenges of translational regenerative medicine: Act on the safety of regenerative medicine.
    Tobita M; Konomi K; Torashima Y; Kimura K; Taoka M; Kaminota M
    Regen Ther; 2016 Jun; 4():78-81. PubMed ID: 31245489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Current status of the regulation and development of cell therapy products in Japan].
    Igarashi Y; Sato Y
    Nihon Yakurigaku Zasshi; 2018; 151(6):254-259. PubMed ID: 29887575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Japanese Laws and the Current Status of Regenerative Medicine in the Tohoku Region.
    Kamano Y; Terajima N; Chiba Y; Suresh VV; Saito M
    J Contemp Dent Pract; 2023 Feb; 24(2):120-128. PubMed ID: 37272144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulatory perspectives of Japan.
    Kusakabe T
    Biologicals; 2015 Sep; 43(5):422-4. PubMed ID: 26028474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A bilingual systematic review of South Korean medical tourism: a need to rethink policy and priorities for public health?
    Xu Q; Purushothaman V; Cuomo RE; Mackey TK
    BMC Public Health; 2021 Apr; 21(1):658. PubMed ID: 33823817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current status of platelet-rich plasma therapy under the act on the safety of regenerative medicine in Japan.
    Arita A; Tobita M
    Regen Ther; 2023 Jun; 23():37-43. PubMed ID: 37063096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding South Korea's Response to the COVID-19 Outbreak: A Real-Time Analysis.
    Jeong E; Hagose M; Jung H; Ki M; Flahault A
    Int J Environ Res Public Health; 2020 Dec; 17(24):. PubMed ID: 33371309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attempts to utilize and integrate traditional medicine in North Korea.
    Lim B; Park J; Han C
    J Altern Complement Med; 2009 Mar; 15(3):217-23. PubMed ID: 19250000
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reimbursement and pricing of regenerative medicine in South Korea: key factors for achieving reimbursement.
    Cho E; Yoo SL; Kang Y; Lee JH
    Regen Med; 2020 Apr; 15(4):1550-1560. PubMed ID: 32356480
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New Governmental Regulatory System for Stem Cell-Based Therapies in Japan.
    Hara A; Sato D; Sahara Y
    Ther Innov Regul Sci; 2014 Nov; 48(6):681-688. PubMed ID: 30227468
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The emergence of a health insurance system in a developing country: the case of South Korea.
    Cho S
    J Health Soc Behav; 1989 Dec; 30(4):467-71. PubMed ID: 2600387
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacovigilance of Regenerative Medicine Under the Amended Pharmaceutical Affairs Act in Japan.
    Inokuma Y
    Drug Saf; 2017 Jun; 40(6):475-482. PubMed ID: 28299610
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [A study on Horace N. Allen's medicine and recognition of Korean body].
    Lee YA
    Uisahak; 2011 Dec; 20(2):291-325. PubMed ID: 22343698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How can we improve patients' access to new drugs under uncertainties? : South Korea's experience with risk sharing arrangements.
    Lee B; Bae EY; Bae S; Choi HJ; Son KB; Lee YS; Jang S; Lee TJ
    BMC Health Serv Res; 2021 Sep; 21(1):967. PubMed ID: 34521408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regenerative Medicine in South Korea: Bridging the Gap Between Authorization and Reimbursement.
    Kim DS; Lee G; Cho H; Bae S
    Front Bioeng Biotechnol; 2021; 9():737504. PubMed ID: 34527662
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Advanced Therapy medicinal products for autologous chondrocytes and comparison of regulatory systems in target countries.
    Kim J; Park J; Song SY; Kim E
    Regen Ther; 2022 Jun; 20():126-137. PubMed ID: 35582708
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regenerative medicine regulatory policies: A systematic review and international comparison.
    Qiu T; Hanna E; Dabbous M; Borislav B; Toumi M
    Health Policy; 2020 Jul; 124(7):701-713. PubMed ID: 32499078
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Establishment of the National Consortium for Regenerative Medicine and National Regenerative Medicine Database in Japan.
    Okada K; Sato Y; Sugiyama D; Sawa Y
    Clin Ther; 2018 Jul; 40(7):1076-1083. PubMed ID: 29958729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in the traditional Korean medical sector as a result of health related legislation.
    Han D; Yoon TH
    Med Law; 2006 Dec; 25(4):685-97. PubMed ID: 17263035
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.